Analysis of Clinical Characteristics and Prognosis of Patients With Periocular Malignant Melanoma in Korea.
Journal
The Journal of craniofacial surgery
ISSN: 1536-3732
Titre abrégé: J Craniofac Surg
Pays: United States
ID NLM: 9010410
Informations de publication
Date de publication:
Historique:
pubmed:
23
7
2021
medline:
5
11
2021
entrez:
22
7
2021
Statut:
ppublish
Résumé
To report the clinical features of 20 patients with malignant melanoma and to evaluate the survival and prognosis of patients with malignant melanoma in Korea. The medical records of 20 patients with malignant melanoma treated between March 2004 and March 2020 were reviewed retrospectively. The demographic data, clinical characteristics, and outcomes were also reviewed. Outcome measures included local recurrence, metastasis, and tumor-related mortality. Prognostic factors associated with recurrence, metastasis, and survival were analyzed using a Cox proportional hazards model. Among the 20 patients with periocular malignant melanoma, 4 (20%) showed local recurrence during follow-up (6.61 ± 6.36 years). The 1-, 5-, and 10-year recurrence rates were 5%, 10.3%, and 24.1%, respectively. 10 (50%) patients developed distant metastasis, mainly involving lung, brain, parotid gland and spine. The 1-, 5-, and 10-year rates of metastasis were 5%, 10.9%, and 35.7%, respectively. Significantly fewer metastases were detected following initial extensive surgical excision (P = 0.04). 8 (40%) patients died of malignant melanoma. The main risk factor for mortality was tumor thickness (HR: 3.88, P < 0.01). Based on Kaplan-Meier survival estimates, the 1-, 5-, and 10-year tumor-related survival rates were 75.8%, 55.6%, and 55.6%, respectively. Tumor thickness is a significant prognostic factor affecting the survival rate. It is important to reduce the metastatic rate via extensive resection without leaving any residual tumor in the margin during surgery.
Identifiants
pubmed: 34292249
doi: 10.1097/SCS.0000000000007800
pii: 00001665-202112000-00037
doi:
Types de publication
Journal Article
Langues
eng
Pagination
2716-2718Informations de copyright
Copyright © 2021 by Mutaz B. Habal, MD.
Déclaration de conflit d'intérêts
The authors report no conflicts of interest.
Références
Shields JA, Shields CL. Introduction to melanocytic tumors of the uvea. In: Shields JA, Shields CL. Intraocular Tumors: A Text and Atlas. Philadelphia, Pa: WB Saunders; 1992:45–60
Zimmerman LE. Melanocytic tumors of interest to the ophthalmologist. Ophthalmology 1980; 87:497–502.
Shields JA, Shields CL, Scartozzi R. Survey of 1264 patients with orbital tumors and simulating lesions: The 2002 Montgomery Lecture, part 1. Ophthalmology 2004; 111:997–1008.
McLaughlin CC, Wu XC, Jemal A, et al. Incidence of noncutaneous melanomas in the US. Cancer 2005; 103:1000–1007.
Lee YJ, Lee C, Kim MK, et al. Conjunctival pigmented lesion: clinicopathological analysis of 85 cases in Korean population. Sci Rep 2019; 9:1–8.
Anastassiou G, Heiligenhaus A, Bechrakis N, et al. Prognostic value of clinical and histopathological parameters in conjunctival melanomas: a retrospective study. Br J Ophthalmol 2002; 86:163–167.
Crawford J. Conjunctival melanomas: prognostic factors a review and an analysis of a series. Trans Am Ophthalmol Soc 1980; 78:467.
Missotten GS, Keijser S, De Keizer RJ, et al. Conjunctival melanoma in the Netherlands: a nationwide study. Invest Ophthalmol Vis Sci 2005; 46:75–82.
Vora GK, Demirci H, Marr B, et al. Advances in the management of conjunctival melanoma. Surv Ophthalmol 2017; 62:26–42.
Tuomaala S, Eskelin S, Tarkkanen A, et al. Population-based assessment of clinical characteristics predicting outcome of conjunctival melanoma in whites. Invest Ophthalmol Vis Sci 2002; 43:3399–3408.
Shields CL, Shields JA, Gündüz K, et al. Conjunctival melanoma: risk factors for recurrence, exenteration, metastasis, and death in 150 consecutive patients. Arch Ophthalmol 2000; 118:1497–1507.
De Potter P, Shields CL, Shields JA, et al. Clinical predictive factors for development of recurrence and metastasis in conjunctival melanoma: a review of 68 cases. Br J Ophthalmol 1993; 77:624–630.
Esmaeli B, Wang X, Youssef A, et al. Patterns of regional and distant metastasis in patients with conjunctival melanoma: experience at a cancer center over four decades. Ophthalmology 2001; 108:2101–2105.
Cohen VM, Ahmadi-lari S, Hungerford JL. Gastric metastases from conjunctival melanoma. Melanoma Res 2007; 17:255–256.
Shields CL, Shields JA. Ocular melanoma: relatively rare but requiring respect. Clin Dermatol 2009; 27:122–133.
Esmaeli B, Roberts D, Ross M, et al. Histologic features of conjunctival melanoma predictive of metastasis and death (an American Ophthalmological thesis). Trans Am Ophthalmol Soc 2012; 110:64.
Shields CL, Markowitz JS, Belinsky I, et al. Conjunctival melanoma: outcomes based on tumor origin in 382 consecutive cases. Ophthalmology 2011; 118:389–395. e382.
Lommatzsch P, Lommatzsch R, Kirsch I, et al. Therapeutic outcome of patients suffering from malignant melanomas of the conjunctiva. Br J Ophthalmol 1990; 74:615–619.
Paridaens A, Minassian D, McCartney A, et al. Prognostic factors in primary malignant melanoma of the conjunctiva: a clinicopathological study of 256 cases. Br J Ophthalmol 1994; 78:252–259.
Paridaens A, McCartney A, Minassian D, et al. Orbital exenteration in 95 cases of primary conjunctival malignant melanoma. Br J Ophthalmol 1994; 78:520–528.
Zhou C, Wang Y, Jia R, et al. Conjunctival melanoma in Chinese patients: local recurrence, metastasis, mortality, and comparisons with Caucasian patients. Invest Ophthalmol Vis Sci 2017; 58:5452–5459.
Damato B, Coupland S. An audit of conjunctival melanoma treatment in Liverpool. Eye 2009; 23:801–809.
Baron S, Tyring SK, Fleischmann WR, et al. The interferons: mechanisms of action and clinical applications. JAMA 1991; 266:1375–1383.
Wuestemeyer H, Sauerwein W, Meller D, et al. Proton radiotherapy as an alternative to exenteration in the management of extended conjunctival melanoma. Graefes Arch Clin Exp Ophthalmol 2006; 244:438.